Age
Item
1. patient's age is 18 years or older, both genders.
boolean
C0001779 (UMLS CUI [1])
Neoplasm Metastasis | Eligibility First line FOLFOX Regimen | Adjuvant therapy Disease nonmetastatic | Neoadjuvant Therapy Disease nonmetastatic
Item
2. patients with metastatic disease who are eligible for first line folfox chemotherapy. adjuvant or neoadjuvant given at least 12 months prior for non-metastatic disease is permitted.
boolean
C0027627 (UMLS CUI [1])
C1548635 (UMLS CUI [2,1])
C1708063 (UMLS CUI [2,2])
C0392943 (UMLS CUI [2,3])
C0677850 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C1518409 (UMLS CUI [3,3])
C0600558 (UMLS CUI [4,1])
C0012634 (UMLS CUI [4,2])
C1518409 (UMLS CUI [4,3])
ECOG performance status
Item
3. ecog performance status ≤ 1
boolean
C1520224 (UMLS CUI [1])
Major surgery Previous | Prior radiation therapy
Item
4. at least 4 weeks from prior major surgery or radiotherapy.
boolean
C0679637 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0279134 (UMLS CUI [2])
Life Expectancy
Item
5. life expectancy >3 months
boolean
C0023671 (UMLS CUI [1])
Hematology | Absolute neutrophil count | Platelet Count measurement
Item
6. hematology: anc ≥ 1.5x109/l; platelets >100x109/l.
boolean
C0200627 (UMLS CUI [1])
C0948762 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
Renal function
Item
7. adequate renal function
boolean
C0232804 (UMLS CUI [1])
Liver function
Item
8. adequate hepatic functions
boolean
C0232741 (UMLS CUI [1])
Cardiac function
Item
9. normal cardiac function
boolean
C0232164 (UMLS CUI [1])
Adjuvant therapy Disease nonmetastatic | Neoadjuvant Therapy Disease nonmetastatic
Item
1. patients who had adjuvant or neoadjuvant therapy for non-metastatic disease given within the last 12 months.
boolean
C0677850 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C1518409 (UMLS CUI [1,3])
C0600558 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C1518409 (UMLS CUI [2,3])
Oxaliplatin
Item
2. patients who had received oxaliplatin within 12 months prior to diagnosis of metastatic disease.
boolean
C0069717 (UMLS CUI [1])
Cancer treatment Illicit Study Protocol
Item
3. patients on concurrent anti cancer therapy other than that allowed in the study.
boolean
C0920425 (UMLS CUI [1,1])
C0332266 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
Steroids | Exception Routine Antiemetics | Inhaled steroids
Item
4. patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
boolean
C0038317 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0205547 (UMLS CUI [2,2])
C0003297 (UMLS CUI [2,3])
C2065041 (UMLS CUI [3])
Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Suspected
Item
5. presence of clinically apparent or suspected brain metastasis.
boolean
C0220650 (UMLS CUI [1])
C0220650 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Myocardial Infarction | Congestive heart failure Severe | Cardiac Arrhythmia
Item
6. patients who have had myocardial infarction, severe congestive heart failure, or significant arrhythmia within the past 6 months.
boolean
C0027051 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0003811 (UMLS CUI [3])
Communicable Disease
Item
7. serious active infection at the time of pre-study screening.
boolean
C0009450 (UMLS CUI [1])
Autoimmune Diseases
Item
8. active or history of autoimmune disorders/conditions.
boolean
C0004364 (UMLS CUI [1])
Pregnancy | Lactation
Item
9. women who are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0022925 (UMLS CUI [2])
Cancer Other
Item
10. concurrent active malignancy.
boolean
C1707251 (UMLS CUI [1])
Ascites | Pleural effusion | Osteoblastic bone metastases Disease Site Solitary
Item
11. ascites, pleural effusions, or osteoblastic bone metastases as the only site of disease.
boolean
C0003962 (UMLS CUI [1])
C0032227 (UMLS CUI [2])
C3854652 (UMLS CUI [3,1])
C0012634 (UMLS CUI [3,2])
C1515974 (UMLS CUI [3,3])
C0205171 (UMLS CUI [3,4])
Cancer Other | Exception Malignant Neoplasms Cured | Exception Malignant Neoplasms Treated Adequate
Item
12. other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than 5 years.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0006826 (UMLS CUI [2,2])
C1880198 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0006826 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C0205411 (UMLS CUI [3,4])
Condition Interferes with Protocol Compliance
Item
13. subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
Allergic Reaction Life Threatening Food | Allergic Reaction Life Threatening Pharmaceutical Preparations
Item
14. patients with history of life threatening allergic reactions to food or drugs
boolean
C1527304 (UMLS CUI [1,1])
C2826244 (UMLS CUI [1,2])
C0016452 (UMLS CUI [1,3])
C1527304 (UMLS CUI [2,1])
C2826244 (UMLS CUI [2,2])
C0013227 (UMLS CUI [2,3])
Peripheral Neuropathy Symptomatic CTCAE Grades
Item
15. patients with symptomatic peripheral neuropathy> grade 1.
boolean
C0031117 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
HIV Seropositivity | Hepatitis B surface antigen positive | Hepatitis C antibody positive
Item
16. known positive hiv, hepatitis b surface antigen or hepatitis c antibody.
boolean
C0019699 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
C0281863 (UMLS CUI [3])